Jan 25 (Reuters) - Adocia Sa:
* ADOCIA ANNOUNCES POSITIVE TOPLINE DATA FROM A DOSE-PROPORTIONALITY STUDY OF BIOCHAPERONE® COMBO IN PEOPLE WITH TYPE 2 DIABETES
* ADOCIA SA - STUDY CONFIRMED PREVIOUS RESULTS THAT BIOCHAPERONE COMBO ACTS SIGNIFICANTLY FASTER AND LASTS SIGNIFICANTLY LONGER THAN HUMALOGMIX
* ADOCIA SA - ALL TREATMENTS WERE WELL TOLERATED
* ADOCIA SA - BOTH PRIMARY ENDPOINTS WERE MET IN STUDY Source text for Eikon: Further company coverage: